Targeting agent antibody conjugates and uses thereof

Patent metadata

Field	Value
Publication number	US-10351626-B2
Application number	US-201414774647-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 14, 2013
Publication date	Jul 16, 2019
Grant date	Jul 16, 2019

Abstract

Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.

First claim

That which is claimed is:

1. A targeting agent-antibody conjugate comprising:
a compound of Formula XI:

and an antibody or antibody fragment that binds an antigen on a cytotoxic effector cell, wherein the wavy line of Formula XI indicates a point of attachment to the antibody or antibody fragment.

2. The targeting agent-antibody conjugate of claim 1 , wherein the antibody or antibody fragment comprises one or more unnatural amino acids.

3. The targeting agent-antibody conjugate of claim 1 , wherein the antigen is a CD3 T-cell co-receptor.

4. The targeting agent-antibody conjugate of claim 1 , wherein the antibody or antibody fragment comprises an anti-CD3 Fab.

5. The targeting agent-antibody conjugate of claim 2 , wherein the one or more unnatural amino acids of the antibody or antibody fragment comprises a p-acetylphenylalanine (pAcF) or a selenocysteine.

6. A pharmaceutical composition comprising the targeting agent-antibody conjugate of claim 1 .

7. A method for treating a cancer in a subject in need thereof, comprising administering an effective amount of the composition of claim 6 .

8. The method of claim 7 , wherein the cancer comprises a prostate cancer, an epithelial cancer, a kidney cancer, lung cancer, a colon cancer, a colorectal cancer, a gastric cancer, a brain cancer, a glioblastoma, a pancreatic cancer, a myeloid leukemia, a cervical cancer, a medullary thyroid carcinoma, a breast cancer, an ovarian cancer, an astrocytoma, an endometrial cancer, a neuroendocrine cancer, a gastroenteropancreatic tumor, a non-Hodgkin's lymphoma, an exocrine pancreatic cancer, an Ewing's sarcoma, or a skin cancer.

Assignees

• The California Institute For Biomedical Res
• Scripps Research Inst

Inventors

• Kim Chanhyuk
• Axup Jun Y
• Yun Hwayoung
• Schultz Peter G
• Ma Jennifer
• Shen Jiayin
• Yang Pengyu

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• C07K16/2887

  against CD20 · CPC title

• C07K16/32

  against translation products of oncogenes · CPC title